2017 Agenda

  • 8:00 am

  • Registration

  • 8:45 am

  • Chair's Welcome and Opening Remarks


    Jeff Kasher, PhD
    President, Patients Can’t Wait

  • Making Innovation a Reality in Big Pharma with Johnson & Johnson and Roche

  • 9:00 am

  • New Leadership in Innovation at Johnson & Johnson

    Parth Chakra-bw

    Parth Chakrabarti, MBA
    Senior Director, Transactions, Johnson & Johnson Innovation, Boston

  • 9:40 am

  • Strategic Innovation at Roche/Genentech


    Vanessa Reddy
    Strategic Innovation Leader, Roche

  • 10:15 am

  • Networking Break

  • Disrupting Patient Outreach, Engagement & Adherence: Progress

  • 10:45 am

  • A Clinical Trial Bus Engaging in Research: Yes, Clinical Trials on Wheels!

    The pioneering Health Research Bus (HRB) has been developed to further public engagement and education in clinical research and to overcome the static reality of clinical trials. The bus acts as a fully functional mobile clinical research facility and contains all the equipment necessary to perform a wide variety of clinical studies. It enables scientists to access a large population of diverse ethnic and socio-economic mix in the surrounding community. In this session, Claire Potter, Acting Head of Research and Knowledge Transfer, University of Birmingham, shares the journey in establishing the initiative and the lessons learned to date.


    Claire Potter
    Acting Head of Research and Knowledge Transfer, University of Birmingham


  • 11:15 am

  • Connecting Patients to Clinical Trials Through an Online Ecosystem: Lilly TrialGuide

    Traditional recruitment campaigns are time consuming, expensive, transactional and no longer optimal. With more patients going online for health information and becoming empowered to make healthcare decisions, Eli Lilly & Company recognizes this shift in patient behavior and is evolving its approach. With Lilly TrialGuide as the centerpiece, a shift to tailored, everlasting patient centric digital recruitment campaigns focuses on content, patient experience and results. In this session, Dr Sara James, Innovation Lead, Clinical Innovation, Eli Lilly & Company discusses the steps they are taking to enable patients to find the information they need through organic searches and earned media instead of sponsors relying exclusively on paid media.

    Sara James

    Sara James, PhD
    Consultant, Adoption Implementation, Clinical Innovation, Eli Lilly & Company

  • 11:45 am

  • The Patient Ambassador Initiative


    Jenny Preston, PhD
    Patient and Public Involvement Manager / Patient and Public Involvement Priority Lead
    NIHR Alder Hey Clinical Research Facility / National Institute for Health Research (NIHR)

    John Molony
    Patient Ambassador

    Keith Wilson
    Patient Ambassador

    Paul Charlton
    Patient Ambassador

    Photo Mark Earthy www.earthyphotography.co.uk This image is protected by Copyright

    Patient Ambassadors from DPharm Europe 2016

  • 12:15 pm

  • What Is the Latest with Brexit’s Impact on Clinical Research?

    With the UK voting to leave the EU, pharmaceutical and life sciences organisations will no doubt be considering the impact of issues ranging from regulations and funding to migration and trade. While the result of the referendum is known, we are only just beginning to get a sense of what shape the UK’s exit will take and the impact this may have on the sector. In this session, Jo Pisani, Partner at Strategy&, PwC UK, will discuss in more detail some of the issues and opportunities that the EU transition presents the Lifesciences industry.


    Jo Pisani, MBA
    Partner at Strategy&, PwC UK

  • 12:35 pm

  • Luncheon

  • Impact of Real World Data

  • 1:45 pm

  • How to Design a Clinical Trial with Real World Data

    Clinical Practice Research Datalink (CPRD) is a not-for-profit research service, jointly funded by the NHS, NIHR and the MHRA, a part of the Department of Health. CPRD has created a seamless system to connect evidence-based recruitment, trial management and data collection. This integrated approach using real world primary care data opens up a wealth of previously untapped clinical research possibilities. In this session, Janet Valentine, Director, CPRD, demonstrates how CPRD has used the data collected in a new trial design.


    Janet Valentine
    Director, Clinical Practice Research Datalink (CPRD)

  • 2:15 pm

  • The Results Are In! Case Study with a Phase 2b Alzheimer Trial in a Hospital Setting

    Bert Hartog, PhD, Director, R&D Operations Innovation, Janssen, shares the full results of a trial simulation from a phase 2b Alzheimer study in three countries with both experienced trial participants and people new to trials. This session demonstrates lessons learned from a powerful way to generate direct insights from new and experienced participants.


    Bert Hartog, PhD
    Director, R&D Operations Innovation, Janssen

  • 2:45 pm

  • Building an Ecosystem of Patient Communication Beyond Trial Participation

    • Be the Partner will discuss how it took a “patient first” perspective in building its platform, using patient input and feedback
    • The firm will present the results from an initial pilot of the platform in a study conducted by a large pharma sponsor
    • Leveraging the success of the pilot of learnings from it and further patient input, Be the Partner will discuss the future of the platform and the opportunity for pharma to create a pre-competitive, patient-centric asset


    Thomas Klein
    Founder and CEO, Be the Partner

  • 3:00 pm

  • Networking Break

  • 3:30 pm

  • Best of Breed Innovation Models - New Collaboratives and Real World Data

    Hakim Yadi_bw

    Hakim Yadi, PhD, OBE
    CEO, The Northern Health Science Alliance

  • 4:00 pm

  • Protocol Simulation: An AstraZeneca Case Study


    Guy Yeoman
    VP, Patient Centricity, AstraZeneca

  • 4:30 pm

  • Innovative Sources & Solutions: Quickfire Disruptors

    This is an opportunity to hear how innovative companies are helping to move clinical trials forward. All presentations focus on solving problems in clinical trials. What is the problem or challenge and how is each company using an innovative solution to solve it? This session will showcase how each company is making change possible.

    Presenting Companies:
    Graham Belgrave-bw
    Graham Belgrave

    Chief Operations Officer

    Biogen Idec
    Jane Rhodes, MBA, PhD

    Senior Director, New Initiatives

    Melissa Harris 

    Senior Account Director 

  • 5:30 pm

  • Cocktail Reception

2017 Agenda

  • 8:00 am

  • Breakfast

  • 8:45 am

  • Co-Chairs’ Opening Remarks


    Sue Collier, BSc, MBchB, DRCOG
    Clinical Development Director and Physician Leader RWE Studies, GSK


    Jeff Kasher, PhD
    President, Patients Can’t Wait

  • Making Innovation a Reality in Big Pharma with Bayer AG

  • 9:00 am

  • Innovation in What You Do at Bayer

    • Driving innovation culture throughout the organization
    • Fostering internal and external collaboration
    • Increasing agility by business experimentation


    Mélanie Héroult
    Innovation Director, Bayer AG

  • 9:30 am

  • The Salford Lung Study: The Latest on Obtaining Real World Evidence

    The pioneering Salford Lung Study is the world’s first phase lll pRCT in asthma and chronic obstructive pulmonary disease (COPD), which recruited 2,800 patients and compared the effectiveness of Relvar Eliipta versus existing treatments. In this session, Dr Sue Collier shares the positive results and the latest on the outcomes and next steps in the analysis of this real world evidence.

    Sue Collier-BW

    Sue Collier, BSc, MBchB, DRCOG
    Clinical Development Director and Physician Leader RWE Studies, GSK

  • 10:15 am

  • Networking Break

  • Where Are They Now?

  • 10:45 am

  • Making History: Crowdfunding Clinical Trials

    Alexander Masters reports on a pioneering new project making global history in clinical trials. For more information listen to Alexander on Pharma Talk Radio here.


    Alexander Masters
    Author, Campaigner and Co-Founder, iCancer.org.uk

  • 11:30 am

  • Building a European Adaptive Trial Delivery Machine for Dementia


    Craig Ritchie, PhD
    Professor of Psychiatry of Ageing, Centre for Clinical Brain Sciences, University of Edinburgh

  • 12:15 pm

  • Luncheon

  • 1:30 pm

  • Strategic Approach to the Siteless Trial Model


    Tomasz Sablinski, MD, PhD
    CEO, Transparency Life Sciences

  • 2:00 pm

  • Innovation at GSK: the mHealth Parade Study

    GSK Innovation team has launched a tool designed to gather in-life data from subjects without the use of traditional investigative sites. This study was designed to gather data on patients with Rheumatoid Arthritis to evaluate the potential for enrollment and compliance in a siteless model.

    In this session Kevin Jenkins, Project Director Clinical Innovation and Digital Platforms and Emilia Quattrocchi, Director Clinical Development, Rheumatology & Autoimmune diseases and Valentin Hamy, Clinical Development Manager will discuss how GSK planned and deployed, and will analyze this study with specific focus on:

    • Vision and Introductions
    • mHealth and Parade Background Fit and Objectives
    • Rheumatoid Arthritis and the Parade Study
    • Data Analysis and Algorithm Development
    • Summary


    Valentin Hamy, PhD
    Clinical Development Manager, GSK


    Kevin Jenkins
    Project Director Clinical Innovation and Digital Platforms, GSK


    Emilia Quattrocchi, MD
    Director Clinical Development, Rheumatology & Autoimmune Diseases, GSK

  • 2:35 pm

  • Town Hall Meeting - A Call to Action

    Our innovative leaders reflect on the past two days and discuss:

    • What does it all mean?
    • How do we take action on the ideas shared?

    Moderated by:
    Kate Moss-bw

    Kate Moss
    Partner, PwC UK


    Jeff Kasher, PhD
    President, Patients Can’t Wait


    Jane Rhodes, MBA, PhD
    Senior Director, New Initiatives, Biogen Idec

  • 3:15 pm

  • Conference Concludes